DAIICHI SANKYO, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Advanced Solid Tumor
Lymphoma

Interventions: Drug: Milademetan

First Posted Date: 2013-06-13

Last Posted Date: 2024-07-18

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 107

Registration Number: NCT01877382

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Columbia University College of Physicians and Surgeons, New York, New York, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 2 locations

A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: DS-7309
Drug: placebo

First Posted Date: 2013-05-27

Last Posted Date: 2013-05-27

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 52

Registration Number: NCT01862939

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Phase 1

Terminated

Conditions: V600-mutated BRAF Unresectable Melanoma
V600-mutated BRAF Metastatic Melanoma
Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

Interventions: Drug: PLX3397
Drug: vemurafenib

First Posted Date: 2013-04-08

Last Posted Date: 2020-05-28

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 13

Registration Number: NCT01826448

Locations: 🇺🇸
University of Colorado, Denver, Aurora, Colorado, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 3 locations

Edoxaban in Peripheral Arterial Disease

Phase 2

Completed

Conditions: Peripheral Arterial Disease

Interventions: Drug: edoxaban
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2013-03-01

Last Posted Date: 2019-02-26

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 203

Registration Number: NCT01802775

Locations: 🇧🇪
Edgem, Edegem, Belgium

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1

Completed

Conditions: Patients With Newly Diagnosed Glioblastoma

Interventions: Drug: PLX3397
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2013-02-13

Last Posted Date: 2020-06-30

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 65

Registration Number: NCT01790503

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
James Cancer Hospital/Ohio State University, Columbia, Ohio, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 6 locations

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: 20 mg ASB17061
Drug: Placebo
Drug: 10 mg ASB17061
Drug: 5 mg ASB17061

First Posted Date: 2012-12-28

Last Posted Date: 2021-02-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 370

Registration Number: NCT01756898

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

Phase 3

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Placebo
Drug: Tivantinib

First Posted Date: 2012-12-24

Last Posted Date: 2021-04-06

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 383

Registration Number: NCT01755767

Effect of Tivantinib on the QTC Interval in Cancer Subjects

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Placebo
Drug: Tivantinib

First Posted Date: 2012-10-03

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 38

Registration Number: NCT01699061

Locations: 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Phase 2

Completed

Conditions: Venous Thrombosis
Deep Vein Thrombosis

Interventions: Drug: edoxaban tosylate
Drug: enoxaparin/unfractionated heparin
Drug: warfarin

First Posted Date: 2012-08-13

Last Posted Date: 2019-02-26

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 85

Registration Number: NCT01662908

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Lymphoma
Advanced Solid Tumor

Interventions: Drug: DS-3078a

First Posted Date: 2012-05-01

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 32

Registration Number: NCT01588678

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy